CCR

Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity

33 views | Dec 28 2023

Inhibiting CCR1 in B-cell lymphoma's microenvironment reprograms protumor macrophages, diminishes immunosuppression, and presents a promising therapeutic avenue for reshaping the tumor milieu and improving patient outcomes. [Read the Full Post]

APX-115, a pan-NADPH oxidase inhibitor, protects development of diabetic nephropathy in podocyte specific NOX5 transgenic mice

0 views | Oct 02 2023

APX-115, a pan-NOX inhibitor, shows potential as a promising therapeutic agent for the treatment of diabetic nephropathy by improving pancreatic beta cell function, reducing lipid levels, restoring kidney damage markers, and exerting anti-inflammatory effects. [Read the Full Post]

C-C motif chemokine receptor 2 inhibition reduces liver fibrosis by restoring the immune cell landscape

37 views | Aug 08 2023

Cenicriviroc (CVC) treatment and CCR2 deletion alleviate liver fibrosis by restoring the immune cell landscape, inhibiting the hepatic accumulation of inflammatory macrophages and neutrophils, and suppressing profibrotic gene transcription through inactivation of the CCR2-STAT1/NFκB/ERK signaling pathways. [Read the Full Post]

Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the Phase 2b TANDEM study

57 views | Aug 08 2023

The combination therapy of tropifexor (TXR) and cenicriviroc (CVC) did not show significant additional efficacy compared to respective monotherapies in terms of alanine aminotransferase (ALT) levels, body weight, or histological endpoints in the treatment of non-alcoholic steatohepatitis (NASH) in a phase 2b study. [Read the Full Post]

TRPM4 gene variation associated with climatic conditions in Chinese cattle

52 views | Apr 15 2023

The study suggests that a missense mutation in the TRPM4 gene is associated with heat tolerance in Chinese cattle and could be a candidate locus for further investigation. [Read the Full Post]

5-Oxoproline Enhances 4-Hydroxytamoxifen-induced Cytotoxicity by Increasing Oxidative Stress in MCF-7 Breast Cancer Cells

65 views | Apr 15 2023

The study found that 5-oxoproline (5-OP) enhances 4-hydroxytamoxifen (4-OHT)-induced cytotoxicity in estrogen receptor (ER)-positive breast cancer cells under normal glucose conditions, while the selective monocarboxylate transporter (MCT) 4 inhibitor Bindarit decreased 4-OHT sensitivity, and MCT1 expression increased under normal glucose conditions. [Read the Full Post]

Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock

88 views | Apr 12 2023

The study found that pirfenidone provided prophylactic and therapeutic benefits for murine endotoxic shock by inhibiting pro-inflammatory cytokines, enhancing interleukin-10, and suppressing apoptotic cells and TGF-beta1 in the liver. [Read the Full Post]

Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial

70 views | Apr 11 2023

The phase 1b trial evaluated the safety, tolerability, and efficacy of inhaled pirfenidone in patients with IPF and showed that the treatment was well-tolerated and may be a safe and effective alternative to oral pirfenidone or nintedanib. [Read the Full Post]

TGFβ1+CCR5+ neutrophil subset increases in bone marrow and causes age-related osteoporosis in male mice

43 views | Mar 12 2023

The study suggests that reducing the numbers of TGFβ1+CCR5+ neutrophils in the bone marrow, potentially through the use of a CCR5 antagonist like maraviroc, could be a treatment for age-related osteoporosis. [Read the Full Post]

Multivariate Chemometric Comparison of Forced Degradation and Electrochemical Oxidation LC-MS Profiles of Maraviroc

74 views | Mar 12 2023

The study found that maraviroc is susceptible to UVA, H2O2, and electrochemical degradation, and suggests that electrochemical methods can be used as a supplement to forced degradation procedures for a quicker and relatively low-cost alternative. [Read the Full Post]